Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and hydrazine

irinotecan has been researched along with hydrazine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML1
Akama, TO; Bobkov, AA; Fukuda, M; Fukuda, MN; Hatakeyama, S; Nakayama, J; Ohyama, C; Shibata, TK; Sugihara, K; Takano, Y; Tamura, N; Wong, SM1
Brohl, AS; Cubitt, CL; Fridley, B; Kahen, E; Reed, DR; Welch, D1

Other Studies

3 other study(ies) available for irinotecan and hydrazine

ArticleYear
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan

2008
Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Dec-06, Volume: 108, Issue:49

    Topics: Amino Acid Sequence; Animals; Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbohydrates; Cell Line, Tumor; Drug Delivery Systems; HCT116 Cells; Humans; Hydrazines; Injections, Intravenous; Irinotecan; Luminescent Measurements; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Mimicry; Molecular Sequence Data; Neoplasms; Neovascularization, Pathologic; Peptides; Protein Binding; Xenograft Model Antitumor Assays

2011
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
    PloS one, 2019, Volume: 14, Issue:9

    Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cyclophosphamide; Depsipeptides; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone Demethylases; Humans; Hydrazines; Irinotecan; Sarcoma, Ewing; Sulfonamides; Vincristine

2019